Circular RNA linked to brain function – Phys.org – Phys.Org

August 10, 2017 Circular RNA can impact normal brain function. Credit: The circular RNA biology Training Network (circRTrain), MDC.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the current issue of Science, Nikolaus Rajewsky and his team at the Berlin Institute of Medical Systems Biology (BIMSB) of the Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC), as well as other collaborators within the MDC and Charit, present data thatfor the first timelink a circular RNA to brain function.

RNA is much more than the mundane messenger between DNA and the protein it encodes. Indeed, there are several different kinds of non-coding RNA molecules. They can be long non-coding RNAs (lncRNAs) or short regulatory RNAs (miRs); they can interfere with protein production (siRNAs) or help make it possible (tRNAs). In the past 20 years, scientists have discovered some two dozen RNA varieties that form intricate networks within the molecular microcosm. The most enigmatic among them are circRNAs, an unusual class of RNAs whose heads are connected to their tails to form a covalently closed ring. These structures had for decades been dismissed as a rare, exotic RNA species. In fact, the opposite is true. Current RNA-sequencing analyses have revealed that they are a large class of RNA, which is highly expressed in brain tissues.

Thousands of circular RNAs exist in nematode worms, mice and humans

In 2013, two pioneering studies that characterized circular RNAs appeared in the journal Nature, one of them by Nikolaus Rajewsky and his team. Intriguingly, most circular RNAs are unusually stable, floating in the cytoplasm for hours and even days on end. The systems biologists proposed thatat least sometimes - circRNAs serve gene regulation. Cdr1as, a large single-stranded RNA loop that is 1,500 nucleotides around, might act as a "sponge" for microRNAs. For example, it offers more than 70 binding sites for a microRNA called miR-7. MicroRNAs are short RNA molecules that typically bind to complementary sequences in messenger RNAs, thereby controlling the amounts of specific proteins produced by cells.

Additionally, Rajewsky and his collaborators mined databases and discovered thousands of different circRNAs in nematode worms, mice and humans. Most of them were highly conserved throughout evolution. "We had found a parallel universe of unexplored RNAs," says Rajewsky. "Since publication the field has exploded; hundreds of new studies have been carried out."

Understanding a circle that is mostly present in excitatory neurons

For the current paper in Science, the systems biologists teamed up with Carmen Birchmeier's lab at the MDC to reconsider Cdr1as. "This particular circle can be found in excitatory neurons but not in glial cells," says Monika Piwecka, one of the first authors of the paper and coordinator of most of the experiments. "In brain tissues of mice and humans, there are two microRNAs called miR-7 and miR-671 that bind to it." In a next step, Rajewsky and his collaborators selectively deleted the circRNA Cdr1as in mice using the genome editing technology CRISPR/Cas9. In these animals, the expression of most microRNAs in four studied brain regions remained unperturbed. However, miR-7 was downregulated and miR-671 upregulated. These changes were post-transcriptional, consistent with the idea that Cdr1as usually interacts with these microRNAs in the cytoplasm.

"This indicates that Cdr1as usually stabilizes or transports miR-7 in neurons by sponging them up, while miR-167 might serve to regulate levels of this particular circular RNA," says Rajewsky. If microRNA floated in the cytoplasm without binding anywhere, it would get broken down as waste. The circle would prevent that and also carry it to new places like the synapses. He adds: "Maybe we should think about Cdr1as not as a 'sponge' but as a 'boat.' It prevents its passengers from drowning and also moves on to new ports."

The changes in microRNA concentration had dramatic effects on the mRNA and proteins produced by nerve cells, especially for a group called "immediate early genes." They are part of the first wave of responses when stimuli are presented to neurons. Also affected were messenger RNAs that encode proteins involved in the maintenance of the animals' sleep-wake cycles.

Cdr1as modulates synaptic responses

Using single-cell electrophysiology, Charit-researcher Christian Rosenmund observed that spontaneous vesicle release at the synapse happened twice as often. The synaptic responses to two consecutive stimuli were also altered. Additional behavioral analyses performed at the MDC mirrored these findings. Even though the mice appeared normal in many ways, they were unable to tune down their responses to external signals such as noises. Similar disruptions in pre-pulse inhibition have been noted in patients suffering from schizophrenia or other psychiatric diseases.

It is an everyday experience how much we depend on this filtering function: When a loud noise suddenly disturbs the quiet atmosphere of a library, you cannot avoid being alarmed. The same bang, however, will seem much less threatening next to a construction site. In this instance, the brain has had the chance to process previous noises and filter out unnecessary information. Therefore, the startle reflex is dampened (pre-pulse inhibition). This basic brain function that allows healthy animals and people to temporarily adapt to a strong stimulus and avoid information overload has now been linked to Cdr1as.

"Functionally, our data suggest that Cdr1as and its direct interactions with microRNAs are important for sensorimotor gating and synaptic transmission," says Nikolaus Rajewsky. "More generally, since the brain is an organ with exceptionally high and diverse expression of circular RNAs, we believe that our data suggest the existence of a previously unknown layer of biological functions carried out by these circles."

Explore further: Research shows that circular RNAs, until now considered non-coding, can encode for proteins

More information: M. Piwecka el al., "Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function," Science (2017). science.sciencemag.org/lookup/ 1126/science.aam8526

A group of scientists in Israel and Germany, led by Prof. Sebastian Kadener from the Hebrew University of Jerusalem, have discovered a protein-encoding function for circular RNA. This kind of RNA molecule is highly active ...

Our genetic information is stored in DNA, tiny strands of nucleic acid that contain instructions for the functioning of our bodies. To express this genetic data, our DNA is copied into RNA molecules, which then translate ...

Proteins are the building blocks of all cells. They are made from messenger RNA (mRNA) molecules, which are copied from DNA in the nuclei of cells. All cells, including brain cells regulate the amount and kind of proteins ...

UCLA research could lead to a simple saliva test capable of diagnosingat an early stagediabetes and cancer, and perhaps neurological disorders and autoimmune diseases.

Scientists face a conundrum in their quest to understand how microRNAs regulate genes and therefore how they influence human disease at the molecular level: How do these tiny RNA molecules find their partners, called messenger ...

Cancer cells are notorious for their genomes gone haywire, often yielding fusion proteinsmash-ups of two disparate genes that, once united, assume new and harmful capabilities. Exactly how such genome scrambling impacts ...

(Phys.org)A team of researchers with the University of Pennsylvania has uncovered the means by which squid eyes are able to adjust to underwater light distortion. In their paper published in the journal Science, the group ...

Scientists at the Universities of Oslo and Liverpool have uncovered the secret behind a goldfish's remarkable ability to produce alcohol as a way of surviving harsh winters beneath frozen lakes.

The gene-editing technology called CRISPR has revolutionized the way that the function of genes is studied. So far, CRISPR has been widely used to precisely modify single-celled organisms and, more importantly, specific types ...

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the current issue of Science, Nikolaus Rajewsky and his team at the ...

In the cells of palm trees, humans, and some single-celled microorganisms, DNA gets bent the same way. Now, by studying the 3-D structure of proteins bound to DNA in microbes called Archaea, University of Colorado Boulder ...

Until recently, the CRISPR-Cas9 gene editing technique could only be used to manipulate DNA. In a 2016 study, University of California San Diego School of Medicine researchers repurposed the technique to track RNA in live ...

Adjust slider to filter visible comments by rank

Display comments: newest first

http://www.creati...ice.html

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:

Circular RNA linked to brain function - Phys.org - Phys.Org

March for Science: Scientists were instructed to stay away – National Herald

Apprehending serious repercussions over what could have been perceived as an anti-government activity, many researchers and scientists were instructed not to participate in the India March for Science on August 9.

The march saw thousands of scientists and science enthusiasts from premier research institutions and colleges of the country taking to streets in 26 cities across the country. It was held to protest government promoting unscientific ideas and budgetary cuts in the funding to research institutes. Hundreds of demonstrators holding placards, reading messages such as Defend science, not defund science, stop killing science for your personal and political agenda and sought respect for research.

Demanding that the government invest 3 per cent of countrys total GDP in the field of research and development, they lamented that the investment remains stagnant at around 0.9 per cent for the past 10 years.

Pertinently, India March for Science follows the global March for Science that was held in April, Washington DC, along with over 600 other cities around the world in April to support scientific research and evidence-based policy making. It was held shortly after US President Donald Trumps inauguration earlier this year, to protest his governments attitude towards science.

Describing climate change an expensive hoax and declaring that numerous environmental protection laws would be rolled back, President Trump had withdrawn the United States from the landmark 2015 global agreement to fight climate change.

In India, however, members of several institutes like Institute of Genomics & Integrative Biology (IGIB)which is a premier Institute of Council of Scientific and Industrial Research (CSIR), engaged in research of national importance in the areas of genomics, molecular medicine, bioinformatics, proteomics and environmental biotechnology, were advised not to participate in the march.

Screen grab of the Email sent to the members of CSIR-IGIB from the director

Citing reasons for issuing instructions to the members of the CSIR-IGIB, its director Dr Sanjay Kumar said that there was no need to hold such a march. Modi government doesnt have an anti-science perspective. It is encouraging science and funding has gone up, he told National Herald, without disclosing the amount of funding that has been increased for his institute in the past three years.

His office in fact gave e-mail instructions to all members of CSIR-IGIB not to participate in the march. In much demonstrations, there is always a possibility of police lathi-charge or any untoward incident can happen if a large gathering turns into a mob. So my first concern is the safety and security of my scientists, he stated, adding that the Modi government is always there to financially support the scientists if there is a mission like Chandrayaan.

I dont understand why a particular group of scientists held such a march. I havent interacted with them, he added, refusing that he had been instructed by higher authorities to advise the members of research body against participating in March for Science.

On August 8, without citing any reasons, an e-mail from the office of CSIR-IGIB directors secretariat, written by his PA Manoj Kumar asked its members to not participate in the march.

The e-mail reads: I am directed to inform all the members of CSIR-IGIB that they are advised not to participate in the March for Science which is being organised tomorrow.

Those who have been holding the governing bodies of research institutes dont have a spine to stand for the promotion of science and scientific temperament or to counter the unscientific ideas being promoted in this country, said a scientist at one CSIR institute on the basis of anonymity, adding that heads of most of the institutesmostly careerist-scientistsperceived that the march could be perceived as an anti-government activity, which will have serious ramifications. They are more concerned about their jobs rather than the discipline of science or the country for that matter.

In this country, a union minister says that India is carrying out scientific research to establish the benefits of cow dung, cow urine, cow milk, curd and clarified butter. Look at the kind of research subjects that are being appreciated and funded by the government, he wondered.

See more here:

March for Science: Scientists were instructed to stay away - National Herald

UCT opens first global research centre on killer fungi – Times LIVE

The worlds first international research centre for tackling fungal infections which kill about 1.3 million people globally every year opened at the University of Cape Town (UCT) on Friday.

The majority of deaths related to fungal infections are in Africa particularly sub-Saharan Africa. Here about 50% of people die as a result of invasive fungal infections.

In 2008 one million cases of cryptococcal meningitis were reported in patients with HIV resulting in more than 500,000 related deaths UCT said in a statement on Friday.

Professor Mark Nicol head of UCTs Division of Medical Microbiology in the Department of Pathology said: "This is a wonderful opportunity to develop a centre of excellence for fungal infections on the African continent. We will have the opportunity to extend the pioneering clinical research on fungal infections taking place at UCT by collaborating with scientists studying the biology and immunology of fungal infections at the world-leading centre [at the University of] Aberdeen [UA].

Now the UA internationally recognised Aberdeen Fungal Group in collaboration with UCT have established the worlds first research centre focused on tackling these diseases in Africa. The R10-million UAs AFGrica Unit will be based at UCTs IDM [Institute of Infectious Disease and Molecular Medicine] headed by Professor Valerie Mizrahi.

Professor Gordon Brown from the Aberdeen Fungal Group who led the establishment of the AFGrica Unit said: Fungal infections are understudied and under-diagnosed compared with other infectious diseases despite their contribution to so many deaths every year.

Fungal infections kill more people in Africa than anywhere else on the planet. The AFGrica Unit is a unique opportunity to address the urgent need to improve basic knowledge and clinical management of fungal infections in Africa.

Go here to see the original:

UCT opens first global research centre on killer fungi - Times LIVE

New version of DNA editing system corrects underlying defects in RNA-based diseases – Phys.Org

August 10, 2017 Muscle cells from a patient with myotonic dystrophy type I, untreated (left) and treated with the RNA-targeting Cas9 system (right). The MBNL1 protein is in green, repetitive RNA in red and the cell's nucleus in blue. MBNL1 is an important RNA-binding protein and its normal function is disrupted when it binds repetitive RNA. In the treated cells on the right, MBNL1 is released from the repetitive RNA. Credit: UC San Diego Health

Until recently, the CRISPR-Cas9 gene editing technique could only be used to manipulate DNA. In a 2016 study, University of California San Diego School of Medicine researchers repurposed the technique to track RNA in live cells in a method called RNA-targeting Cas9 (RCas9). In a new study, published August 10 in Cell, the team takes RCas9 a step further: they use the technique to correct molecular mistakes that lead to microsatellite repeat expansion diseases, which include myotonic dystrophy types 1 and 2, the most common form of hereditary ALS, and Huntington's disease.

"This is exciting because we're not only targeting the root cause of diseases for which there are no current therapies to delay progression, but we've re-engineered the CRISPR-Cas9 system in a way that's feasible to deliver it to specific tissues via a viral vector," said senior author Gene Yeo, PhD, professor of cellular and molecular medicine at UC San Diego School of Medicine.

While DNA is like the architect's blueprint for a cell, RNA is the engineer's interpretation of the blueprint. In the central dogma of life, genes encoded in DNA in the nucleus are transcribed into RNA and RNAs carry the message out into the cytoplasm, where they are translated to make proteins.

Microsatellite repeat expansion diseases arise because there are errant repeats in RNA sequences that are toxic to the cell, in part because they prevent production of crucial proteins. These repetitive RNAs accumulate in the nucleus or cytoplasm of cells, forming dense knots, called foci.

In this proof-of-concept study, Yeo's team used RCas9 to eliminate the problem-causing RNAs associated with microsatellite repeat expansion diseases in patient-derived cells and cellular models of the diseases in the laboratory.

Normally, CRISPR-Cas9 works like this: researchers design a "guide" RNA to match the sequence of a specific target gene. The RNA directs the Cas9 enzyme to the desired spot in the genome, where it cuts DNA. The cell repairs the DNA break imprecisely, thus inactivating the gene, or researchers replace the section adjacent to the cut with a corrected version of the gene. RCas9 works similarly but the guide RNA directs Cas9 to an RNA molecule instead of DNA.

The researchers tested the new RCas9 system on microsatellite repeat expansion disease RNAs in the laboratory. RCas9 eliminated 95 percent or more of the RNA foci linked to myotonic dystrophy type 1 and type 2, one type of ALS and Huntington's disease. The approach also eliminated 95 percent of the aberrant repeat RNAs in myotonic dystrophy patient cells cultured in the laboratory.

Another measure of success centered on MBNL1, a protein that normally binds RNA, but is sequestered away from hundreds of its natural RNA targets by the RNA foci in myotonic dystrophy type 1. When the researchers applied RCas9, they reversed 93 percent of these dysfunctional RNA targets in patient muscle cells, and the cells ultimately resembled healthy control cells.

While this study provides the initial evidence that the approach works in the laboratory, there is a long way to go before RCas9 could be tested in patients, Yeo explained.

One bottleneck is efficient delivery of RCas9 to patient cells. Non-infectious adeno-associated viruses are commonly used in gene therapy, but they are too small to hold Cas9 to target DNA. Yeo's team made a smaller version of Cas9 by deleting regions of the protein that were necessary for DNA cleavage, but dispensable for binding RNA.

"The main thing we don't know yet is whether or not the viral vectors that deliver RCas9 to cells would illicit an immune response," he said. "Before this could be tested in humans, we would need to test it in animal models, determine potential toxicities and evaluate long-term exposure."

To do this, Yeo and colleagues launched a spin-out company called Locana to handle the preclinical steps required for moving RCas9 from the lab to the clinic for RNA-based diseases, such as those that arise from microsatellite repeat expansions.

"We are really excited about this work because we not only defined a new potential therapeutic mechanism for CRISPR-Cas9, we demonstrated how it could be used to treat an entire class of conditions for which there are no successful treatment options," said David Nelles, PhD, co-first author of the study with Ranjan Batra, PhD, both postdoctoral researchers in Yeo's lab.

"There are more than 20 genetic diseases caused by microsatellite expansions in different places in the genome," Batra said. "Our ability to program the RCas9 system to target different repeats, combined with low risk of off-target effects, is its major strength."

Explore further: For first time, scientists use CRISPR-Cas9 to target RNA in live cells

More information: Cell (2017). DOI: 10.1016/j.cell.2017.07.010

The genetic code stored in DNA determines everything from the color of our eyes to our susceptibility to disease. This has motivated scientists to sequence the human genome and develop ways to alter the genetic code, but ...

CRISPR-Cas9 gene editing is based on a tactic bacteria developed to protect themselves from viruses.

A powerful scientific tool for editing the DNA instructions in a genome can now also be applied to RNA, the molecule that translates DNA's genetic instructions into the production of proteins. A team of researchers with Berkeley ...

More and more scientists are using the powerful new gene-editing tool known as CRISPR/Cas9, a technology isolated from bacteria, that holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy ...

Scientists at the Center for Genome Engineering, within the Institute for Basic Science (IBS), in collaboration with KIM Eunji (ToolGen Inc.) and KIM Jeong Hun (Seoul National University) have engineered the smallest CRISPR-Cas9 ...

A study in The Journal of Cell Biology by scientists at the University of Massachusetts Medical School reveals important new details about the inner workings of the CRISPR-Cas9 machinery in live cells that may have implications ...

Researchers studying turtle-headed seasnakes living on coral reefs in the Indo-Pacific noticed something unusual about the snakes' color patterns: seasnakes living in more pristine parts of the reef were decorated with black-and-white ...

Until recently, the CRISPR-Cas9 gene editing technique could only be used to manipulate DNA. In a 2016 study, University of California San Diego School of Medicine researchers repurposed the technique to track RNA in live ...

The gene-editing technology called CRISPR has revolutionized the way that the function of genes is studied. So far, CRISPR has been widely used to precisely modify single-celled organisms and, more importantly, specific types ...

Chimpanzees of all ages and all sexes can learn the simple circular relationship between the three different hand signals used in the well-known game rock-paper-scissors. Even though it might take them longer, they are indeed ...

If you've got plenty of burgers and beers on hand and your own stomach is full, an uninvited guest at your neighborhood barbecue won't put much strain on you.

Researchers at Newcastle University (UK) found that European sea bass experienced higher stress levels when exposed to the types of piling and drilling sounds made during the construction of offshore structures.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:

New version of DNA editing system corrects underlying defects in RNA-based diseases - Phys.Org

Statistical component model to identify associations between chemicals and toxicological effects – Medical Xpress

August 10, 2017 The component model describes statistical links between chemicals and the effect of their molecular toxins. Credit: Juuso Parkkinen, Aalto University

The joint Aalto University, Karolinska Institute and Institute for Molecular Medicine Finland (FIMM) study included over 1,300 known pharmaceutical molecules, on which there is a wealth of measurement data available.

'The study uses systematic data-driven analysis to combine toxicity measurements taken on cell lines with gene expression responses describing gene activation. Toxicity includes growth inhibitory and cell killing effects. The method developed in the study makes it possible to more accurately predict the toxicity of new molecules because it makes use of advanced statistical methods and much bigger datasets than before,' explains Juuso Parkkinen, who completed his doctoral dissertation at Aalto University.

At present, toxicity is primarily measured by means of animal testing. Thanks to this new method, animal testing can be partly replaced in the future by a combination of cell line testing and statistical modelling. This would also result in considerable cost savings for pharmaceutical development.

'The new prediction method can be applied to new pharmaceutical molecules and other chemicals currently in product development to eliminate possible toxic molecules,' adds Parkkinen.

Advances in statistical machine learning and artificial intelligence methods have risen to play a crucial role in many application areas in addition to medical research.

'Juuso Parkkinen is an excellent example of the usefulness of Aalto University's artificial intelligence research and doctoral studies: He wrote his dissertation on medicinal applications in my research group and then transferred to Reaktor to apply data science to a wide range of business needs,' praises Parkkinen's dissertation adviser, Professor Samuel Kaski.

Explore further: Novel method to detect toxic effects of chemicals could reduce need for animal testing

More information: Pekka Kohonen et al. A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury, Nature Communications (2017). DOI: 10.1038/ncomms15932

A new report by the National Academies of Sciences, Engineering, and Medicine proposes a strategy that the U.S. Environmental Protection Agency (EPA) should use to evaluate the evidence of adverse human health effects from ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:

Statistical component model to identify associations between chemicals and toxicological effects - Medical Xpress

New Haven doctor works to repair central nervous system injuries – West Hartford News

NEW HAVEN >> There is now no way to regenerate severed nerves in the central nervous system, but Dr. Stephen M. Strittmatter is confident hes found a way to repair them.

Hes even founded a company, ReNetX Bio Inc., to shepherd his new therapy through the maze of regulations, clinical trials and manufacturing processes, ultimately hoping to cure patients with devastating injuries.

We have this amazing, complex neural network that manages all our functions, stemming from the brain and spinal cord, said Strittmatter, professor of neurology and neuroscience in the Yale School of Medicine.

When a nerve fiber, or axon, in the central nervous system is damaged, such as in a paralyzing spinal cord injury, it doesnt grow back. Even though the nerve cell is still healthy in the adult brain or spinal cord, it cant grow and therefore function doesnt come back, he said.

(The central nervous system, which manages all our functions, is separate from the peripheral nervous system, which performs other tasks, such as carrying stimuli from our senses, and which can regenerate.)

The axon, which starts at the cell body, or soma, can extend up to a meter in length, Strittmatter said. If the cell were the size of a baseball, the extension, the nerve fiber, would be the width of a pencil and be a quarter of a mile long, he said.

Strittmatter said he has investigated why nerve fibers cant grow in adults, and that led us to the idea that there are inhibitors that are present in the adult brain and spinal cord. They stop the axons from growing back to where theyre supposed to be.

In fact, there are three such inhibitors, called Nogo, MAG and OMgp, which exist in the myelin that coats the nerve fibers. They stick to the axon and tell it not to grow, Strittmatter said.

He and the researchers in his lab studied ways to stop the inhibitors from attaching to the axon. So we developed this protein, which we call Nogo Trap Its sort of like a double negative; it blocks the inhibitors [and] those new connections allow function to be recovered, he said.

So far, the therapy looks promising. Weve done experiments here that have shown that that works after rats and mice have spinal cord injuries, he said.

Now, ReNetX Bio, a new name for a company founded in 2010 as Axerion Therapeutics, faces the long process of turning an experimental therapy into a marketable drug, which they hope also will be effective for stroke and glaucoma.

Thats what the company is about, bringing it out of the lab and into the clinic, Strittmatter said.

The next step is getting Food and Drug Administration approval of Nogo Trap, also known as Axer-204, as an investigative new drug, which allows phase one clinical trials. That initial phase is only concerned with the drugs safety. The second and third phases test whether or not the drug is effective.

Erika R. Smith, named CEO of ReNetX in July, said there is a long list of other tasks to be addressed, including toxicology testing, scaling up manufacture of the drug and lots of paperwork. A lot of boxes get checked to make sure its OK to try in a clinical setting, she said.

Both Smith and Strittmatter said there are advantages to forming their own company.

I guess I feel like being involved I can help make sure that the right clinical trials are done, Strittmatter said.

Smith added, Theres a lot of challenges in early research that a lot of pharma companies arent willing to take the risk themselves. A lot of times companies wont come in really early.

Along the way, theres all kinds of roadblocks, things we cant expect, Strittmatter said. Drugs might get degraded faster in one species than another or there could be secondary complications like infections.

Were very excited that the experiments that have happened in the lab have gone very well, he said. However, there is a risk. Experimental animal studies can look great but maybe only 20 percent of the time can that be turned into a drug that can be used in people, he said.

But Smith noted the substantial funding that has come into the company to this point were estimating $15 million that has gotten the program to where it is. Much of that support has come from the National Institutes of Health, she said.

The company has a staff of five and is seeking to hire a chief medical officer, Smith said.

Yale University holds intellectual property rights and is a part owner of ReNetX. The company has licensed those patents from Yale so they can go on to do sales and clinical development, Strittmatter said. Yale would receive royalties if it were eventually sold as a drug.

The end goal that it gets to people and it makes a difference in their lives, Strittmatter said.

Smith said, The big picture of this is its a whole new paradigm change for any kind of injury in the central nervous system.

Call Ed Stannard at 203-680-9382.

Read the rest here:

New Haven doctor works to repair central nervous system injuries - West Hartford News

Height, selected genetic markers and prostate cancer risk: results … – UroToday

Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.

We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.

The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180cm are at a 22% increased risk as compared to men with height <173cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.

There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.British Journal of Cancer advance online publication 1 August 2017; doi:10.1038/bjc.2017.231 http://www.bjcancer.com.

British journal of cancer. 2017 Aug 01 [Epub ahead of print]

Artitaya Lophatananon, Sarah Stewart-Brown, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, David E Neal, Freddie C Hamdy, Jenny L Donovan, Graham G Giles, Liesel M Fitzgerald, Melissa C Southey, Paul Pharoah, Nora Pashayan, Henrik Gronberg, Fredrik Wiklund, Markus Aly, Janet L Stanford, Hermann Brenner, Aida K Dieffenbach, Volker Arndt, Jong Y Park, Hui-Yi Lin, Thomas Sellers, Chavdar Slavov, Radka Kaneva, Vanio Mitev, Jyotsna Batra, Amanda Spurdle, Judith A Clements, APCB BioResource , PRACTICAL consortium , Douglas Easton, Rosalind A Eeles, Kenneth Muir

Centre of Epidemiology, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK., Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK., Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK., Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK., Nuffield Department of Surgical Sciences John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK., School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK., Cancer Epidemiology Centre, The Cancer Council Victoria, 615 St Kilda Road, Melbourne, Victoria 3004, Australia., Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia., Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge CB1 8RN, UK., Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 10435, Sweden., Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany., German Cancer Consortium (DKTK), Heidelberg 69120, Germany., Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA., Biostatistics Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA., Department of Urology and Alexandrovska University Hospital, Medical University, Sofia 1431, Bulgaria., Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, 2 Zdrave Str., Sofia 1431, Bulgaria., Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane 4006, Australia., Molecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane 4006, Australia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/28765617

Read more here:

Height, selected genetic markers and prostate cancer risk: results ... - UroToday

Indian Scientists Resurrect World War Era Drug To Fight Malaria – Outlook India

A neglected and old anti-parasitic drug used during the World War II is emerging as a new weapon in the fight against malaria as malaria parasite becomes resistant to currently available drugs.

A group of Indian researchers have resurrected acriflavine or ACF which was used as an anti-parasite drug in the last century, and have found it to be effective against malaria parasite. Now they are working to make this molecule more effective using nanotechnology.

Advertisement opens in new window

Researchers at the Special Centre for Molecular Medicine at Jawaharlal Nehru University (JNU) have got a patent for antimalarial properties of ACF. They have now joined hands with scientists at the National Institute of Immunology (NII) to develop a nano-formulation of the dug and to study its potential in animal models. The Department of Biotechnology (DBT) is funding this joint effort.

ACF was previously used as a trypanocidal agent against a range of infections during World War II. But due to preferential use of chloroquine for treatment of malaria, its antimalarial activity was never investigated. It was used as an antibacterial and anti-parasitical agent but it was not known as antimalarial agent. We have found that it is effective as an antimalarial molecule also, said Prof Suman Dhar of JNU. We believe nanoformulation of ACF will help release the molecule slowly into the host. This will increase its stability, and it will be then conjugated with specific antibodies to make it more specific.

The researchers have already shown that ACF inhibits the growth of both chloroquine-sensitive and chloroquine-resistant strains of human malarial parasite, Plasmodium falciparum. It was also found to clear malarial infection from bloodstreams of mice infected with Plasmodium berghei. In addition, they have found that ACF is preferentially accumulated in the parasitized red blood cells.

Advertisement opens in new window

Chloroquine and pyrimethamine, which were used as primary chemotherapeutic drugs, are of little use now since the parasite has developed resistance to them. Though there is a decline in global burden of malaria continues to be a major health problem in many countries. Recent reports of resistance to artemisinin, the only effective antimalarial drug at present, are causing concern among health agencies globally.

The team of researchers includes Prof Suman Dhar from Special Center for Molecular Medicine at JNU; Dr Jaydeep Bhattacharya and Dr Deepak Gaur from School of Biotechnology at JNU; and Dr Agam P. Singh from NII, New Delhi.

(Indian Science Wire)

Read the original post:

Indian Scientists Resurrect World War Era Drug To Fight Malaria - Outlook India

MHHS earns pair of accreditations – Citizentribune

Morristown-Hamblen Healthcare System was recently awarded a three-year term of accreditation in computed tomography (CT) and nuclear medicine as the result of a recent review by the American College of Radiology (ACR).

These accreditations join a line-up for the hospitals imaging services including accreditations for general ultrasound and breast imaging resulting in the hospital being named a Breast Imaging Center of Excellence.

This means this community has access to a high level of imagining quality, Emily M. Blomenberg, MBA, RT(R), CRA, director of imaging services at MHHS, said. When you come to Morristown-Hamblen, you know youll be treated the same way each time because we have a set requirement which involves the highest quality care possible in the imaging world.

It also means, youre going to have a safe experience. Safety is extremely important, she continued. I want that for my own family, and I want that here for my patients as well. Youll have a high-quality, consistent and safe environment in Morristown.

CT scanning sometimes called cat scanning is a noninvasive medical test that helps physicians diagnose and tailor treatments for various medical conditions. A CT scan can be used to study all parts of the body such as the chest, abdomen, pelvis, an arm or leg. It can take pictures of body organs such as the liver, pancreas, intestines, kidneys, bladder, adrenal glands, lungs and heart. And it can also study blood vessels, bones and the spinal cord.

Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material, ingested by the patient, to diagnose and treat a variety of disease including many types of cancer, heart disease and certain other abnormalities within the body. Depending on the type of nuclear medicine exam, the radiotracer is either injected into the body, swallowed or inhaled as a gas and eventually accumulates in the organ or area of the body being examined. Radioactive emissions from the radiotracer are detected by a special camera or imaging device that produces pictures and provides molecular information. Nuclear medicine helps physicians do things such as visualize heart blood flow and function, assess damage to the heart following a heart attack, scan lungs for respiratory and blood flow problems, evaluate bones for fractures, detect the early onset of neurological disorders such as Alzheimers disease and stage cancer by determining the presence or spread of cancer in various parts of the body.

The earning of the accreditations for these two departments and others earned prior, required the consistent work of all radiologic technologists. It recognizes their ability to produce high-quality work in a consistent manner and to provide the safest environment possible to patients.

This is not possible without my direct staff. This isnt me or the hospital doing this. This is technologists working directly with patients. They did this, Blomenberg said. They had to adjust to be sure everything was appropriate in these images. They have learned in the process and can be certain they are providing the highest quality of care. I just want to thank them.

The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities meeting ACR Practice Parameters and Technical Standards after a peer-review evaluation by board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures and quality assurance programs are assessed. The findings are reported to the ACR Committee on Accreditation, which subsequently provides the practice with a comprehensive report that can be used for continuous practice improvement.

The ACR, founded in 1924, is a professional medical society dedicated to serving patients and society by empowering radiology professionals to advance the practice, science and professions of radiological care. The College serves more than 37,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services.

Continue reading here:

MHHS earns pair of accreditations - Citizentribune

U.S. News & World Report Ranks UK Chandler Hospital Best in the … – UKNow (press release)

LEXINGTON, Ky. (Aug. 8, 2017)UK HealthCares University of Kentucky Albert B. Chandler Hospital remains the No. 1 hospital in Kentucky and the Bluegrass Region, according to the U.S. News & World Report's Best Hospitals Rankings released today.

In addition, four major health care areas have achieved top 50 national rankings, three of them for the first time. UK HealthCare rankings included: #50 in Cancer, #44 in Neurology and Neurosurgery, #43 in Geriatrics, and #37 in Diabetes and Endocrinology.

Along with the Top 50 rankings, UK HealthCare is ranked as high-performing in five other adult specialties Gastroenterology and GI Surgery; Nephrology; Orthopedics; Pulmonology; and Urology. Additionally, the health care system was designated high performing in eight common adult procedures and conditions: Aortic Valve Surgery, Heart Bypass Surgery, Heart Failure, Colon Cancer Surgery, Chronic Obstructive Pulmonary Disease (COPD), Hip Replacement, Knee Replacement, and Lung Cancer Surgery.

As many patients in the Commonwealth struggle with some of the most complex health issues, these recognitions cement UK HealthCare's role as the major health care system best equipped to deal with our state's unique health needs, said Dr. Michael Karpf, University of Kentucky executive vice president for health affairs.

We are committed to providing the best programs and best care available in Kentucky so that no one has to travel far from home for world-class advanced specialty care and these rankings speak to the hard work and dedication of our physicians, nurses and our entire health care team, Karpf said.

This years U.S. News & World Report rankings cover nearly every hospital in every community nationwide. According to survey officials, the rankings are grounded in objective data and offer patients a deep, rich resource on their hospital choices. Over 70 percent of the rankings are based on objective data, with U.S. News analyzing more than 2,600 metrics across 21 data-driven specialties and procedures and conditions. The result is thousands of data points on hospitals that excel at treating the most challenging cases, those that do best in more routine procedures, like knee replacements, and those that provide top local care.

UK HealthCare is a place where you feel safe because you know we're ready no matter the situation or illness, said Colleen Swartz, UK HealthCares chief administrative officer. If you have someone you love who lives in Kentucky you will need UK HealthCare at some point in time. Whether it's someone with a newly diagnosed cancer, or a premature baby, or a critically ill or injured child, or brother or mother or sister, you want to know that a place like this is ready to go when you need us.

Cancer care was included in the top 50 for the first time although it has consistently been designated as High Performing for many years. Still, the move up is indicative of the Markey Cancer Centers continued emphasis on providing exemplary care as the states only National Cancer Institute (NCI)-designated center.

We see 50 percent of our patients coming from Eastern Kentucky which has some of the highest rates of cancer in the country particularly lung cancer and colon cancer. So, the Markey Cancer Center is vitally important to our region, said Dr. Mark Evers, director of the Markey Cancer Center.

Since 2016, UK HealthCare has gone from one specialty top-50 ranking Geriatrics, which moved up two spots from #45 to #43 to having four major adult specialties nationally ranked.

This is the first time our programs at UK in neuro (neurology and neurosurgery) have achieved national rankings, said Dr. Larry B. Goldstein, the Ruth L. Works Professor and chair of the UKDepartment of Neurology, and co-director of the Kentucky NeuroscienceInstitute (KNI). This is something we've been working on for the past two years, and it's wonderful to be able to have our faculty and staff receive this recognition for all the great things they're doing.

Fellow KNI co-director Linda Van Eldik, who also is director of the UK Sanders-Brown Center on Aging, was pleased with national rankings in Neurology and Neurosurgery as well as Geriatrics. This is really a culmination of the work we've been doing for many years in the areas of brain, Van Eldik said. It's recognition from the outside that we already knew that we were doing cutting-edge work and we are continuing to enhance our excellence.

Dr. Shawn Caudill, professor and chief of the Division of General Internal Medicine and Womens Health, sees increasingly more geriatric patients in UK HealthCares outpatient clinics. (The rankings) are a reflection of why we have such a larger aging population than we had before, Caudill said. Weve had lot of success on overcoming the things that used to kill people heart attacks, strokes, lung disease and weve done interventions to help keep people going longer and now it is important for us to continue to help take care of them.

This years rankings also included a major leap for UKs diabetes and endocrinology program. The previously unranked adult specialty is now 37th in the country, a testament to both the clinical care and research at UKs Barnstable-Brown Diabetes Center. We are one of the few places in Kentucky where all these services are provided either under one roof or where we can engage people to help you in all these different arenas, said Dr. John Fowlkes, director of the Barnstable Brown Diabetes Center.

This collaboration and patient-centered care offered at the Barnstable Brown Diabetes Center provides patients with outstanding clinical care throughout their lifespan and for all aspects of their health, added Dr. Lisa Tannock, chief of the Division of Endocrinology and Molecular Medicine. Our physicians, advancedpractice providers (APPs), endocrinology fellows and staff, including expert certified diabetes educators, continually seek opportunities to pass on advanced patient care based on our ongoing research into the best ways to prevent and treat diabetes and endocrine diseases.

In acknowledging all of UK HealthCares national rankings and achievements, one common factor is always first to be attributed to success the people who work there.

I've been here almost a year and a half and to see what the University of Kentucky and UK HealthCare has achieved, really in a short time is remarkable, said UK College of Medicine Dean Dr. Robert DiPaola. And to see the passion of the people here behind the scenes doing the things that make a difference for our patients it is absolutely amazing. I know that going forward, we will continue this trajectory.

Originally posted here:

U.S. News & World Report Ranks UK Chandler Hospital Best in the ... - UKNow (press release)

Experts call for national policy on integrative medicine – India … – India Education Diary

Kochi: The Government needs to formulate a national policy on the integration of Ayurveda with allopathy so that India can take its rightful place as the global leader in integrative medicine, said experts assembled at Indias biggest conference on integrative Ayurveda and modern medicine at Kochis Amrita Institute of Medical Sciences. The two-day event called Amrita Samyogam, in which more than 60 experts and 1,000 delegates from around the world participated, was held in collaboration with Amrita Universitys School of Ayurveda. It was inaugurated by Dr. Rajesh Kotecha, Special Secretary, Ministry of AYUSH.

The Conference brought together allopathic doctors, Ayurveda practitioners and modern scientists on a common platform to identify strategies for integrating Ayurveda with Allopathy in the management of cancer, auto-immune diseases like arthritis, diabetes, neuro-degenerative diseases, and mental health.

Speaking at the event, Shri Vaidya Rajesh Kotecha, Special Secretary, Ministry of AYUSH, said: In integrative health, all streams of health sciences come together in a synergistic manner to positively impact health outcomes. The Government is very serious about promoting a model where experts in different domains contribute to the health science, and migration of knowledge occurs between each stream. Indian healing systems are holistic and intuitive they cannot fully fit into all parameters demanded by Western medicine. The government is setting up a nationwide AYUSH grid connecting all hospitals and research labs to record case histories and observations so that a huge amount of evidences can be generated through data analytics about the efficacy of Ayurveda. While robust research is being conducted into Ayurveda, the problem arises in implementation of integrative medicine at the level of public health. This is because Ayurveda is still not accepted as a science by the Allopathic community. The Government of India has decided to extend its full support to Amrita Universitys initiative on integrative medicine.

Said Dr. P Ram Manohar, Research Director, Amrita Centre for Advanced Research in Ayurveda: We have a pluralistic healthcare system which is officially promoted, but the irony is that there is no national policy for integrative medicine in the country. The thrust for such integration is currently coming from the patients, who are left to decide for themselves which system of medicine is best suited for them. This can be dangerous as most patients are not well-informed. The trend of integrative medicine is on the rise worldwide and India needs to emerge as the leader in the field. There is a need for practitioners of Ayurveda and allopathy to collaborate and work together as one multi-disciplinary team to deliver better healthcare. We need to develop integrated clinical trials and integrated practice guidelines for practitioners across different healthcare systems.

Said Prof. Shantikumar Nair, Director, Centre for Nanosciences & Molecular Medicine, Amrita University: Allopathic medicine has distinguished itself with molecular level diagnostics and therapy. However, in many chronic conditions like diabetes, arthritis and neurodegenerative and cardiovascular diseases, allopathic care does not promise cure. While disease management is possible with allopathic drugs, they have side-effects due to the use of synthetic elements. In Ayurveda, treatment is through natural herbal medications which can have significant potency and potential for substantial improvement in several disease conditions as well as less deleterious side effects. The main drawback of Ayurveda is the lack of scientific validation and data documentation as per evidence-based criteria, which prevents its better acceptance and recognition.

Added Dr. Christian Kessler, Internal Medicine Specialist, Charite Medical University, Germany: Ayurveda is a highly complex and whole medical system. Through its unique multi-modality therapeutic approach, it tackles issues related to health and disease at a systems level rather than unidimensional physical phenomena of single organs or cells. While modern biomedicine is currently rediscovering such inter-relationships in disciplines like psycho-neuro-immunology or psychosomatics, this has been at the heart of Ayurveda for thousands of years. Therefore, Ayurveda can be a great of source of inspiration for Western medicine, particularly in the emerging fields of personalized medicine, self-effectiveness and a strong emphasis on restoring health instead of focusing on disease only.

The Conference focused on evidence-based practice guidelines for cross-referrals and combination therapy, understanding the biological mechanisms underlying integrative care, and integration of modern technological tools in Ayurvedic diagnostics, treatment procedures and drug delivery. An International Journal of Integrative Health was launched at the event and a Society for Integrative Health was established to promote the development of Integrative Medicine in India.

Eminent medical experts who attended the Conference included: Dr. Jeffrey White, Director of National Cancer Institute, USA; Dr. Daniel Furst, Rheumatologist at University of California; Dr. Nereo Bresolin, Neurologist, University of Milan; Dr. Christian Kessler, Internal Medicine Specialist, Charite Medical University, Germany; Dr. Valdis Pirags, Diabetologist, University of Latvia; Dr. Maryam Matar, Genetics Specialist, UAE; Dr. Ravi Mehrotra, Director, National Institute for Cancer Prevention and Research, Noida, Dr. B.N. Gangadhar, Director, NIMHANS, Bengaluru; Dr. Rama Jayasundar, Professor, All India Institute of Medical Sciences, New Delhi, Dr. Ketaki Bapat, Scientific Advisor to the Government of India, and many others.

Read this article:

Experts call for national policy on integrative medicine - India ... - India Education Diary

Call to form nat’l policy on integrative medicine- The New Indian … – The New Indian Express

KOCHI: Stressing the need to strengthen the healthcare system, Amrita Samyogam 2017 - International Conference on Integrative Ayurveda and Modern Medicine - has urged the Central Government to form a national policy on the integration of ayurveda and allopathy.

Inaugurating the event, Dr Rajesh Kotecha, Special Secretary, Ministry of Ayush, said a policy on integrative medicine would help improve the health sector. Once the policy is formulated, the country can become the global leader in integrative medicine, he said.

The two-day-event is being jointly organised by Amrita Universitys School of Ayurveda and Amrita Institute of Medical Sciences. The conference has brought together allopathic doctors, ayurveda practitioners and modern scientists on a common platform to identify strategies for integrating ayurveda with allopathy in the management of cancer, auto-immune diseases like arthritis and diabetes, neuro-degenerative diseases and mental health.

Kotecha said in integrative health, all streams of health sciences come together in a synergistic manner to positively impact the health outcome. The government is serious about promoting a model where experts in different domains contribute to health science and some transfer of knowledge occurs between each stream. Indian healing systems are holistic and intuitive - by definition, they cannot fully fit into all parameters demanded by western medicine, he said.

AYUSH grid

Kotecha said the government was setting up a nationwide AYUSH grid connecting all hospitals and research labs to record case histories and observations so that a huge amount of evidence can be generated through data analytics about the efficacy of ayurveda. While robust research is being conducted in ayurveda, the problem arises in the implementation of integrative medicine at the level of public health. This is because ayurveda is still not accepted as a science by the allopathic community. The Government of India has decided to extend its full support to Amrita Universitys initiative on integrative medicine, he said.

P Ram Manohar, research director, Amrita Centre for Advanced Research in Ayurveda, said the trend of integrative medicine is on the rise worldwide and India needs to emerge as the leader in the field. There is a need for practitioners of ayurveda and allopathy to collaborate and work together as one multi-disciplinary team to deliver better healthcare. We need to develop integrated clinical trials and integrated practice guidelines for practitioners across different healthcare systems, Manohar said. Shantikumar Nair, director, Centre for Nanosciences and Molecular Medicine, Amrita University, said allopathic medicine has distinguished itself with molecular level diagnostics and therapy. However, in many chronic conditions like diabetes, arthritis and neurodegenerative and cardiovascular diseases, allopathic care does not promise the cure.

Originally posted here:

Call to form nat'l policy on integrative medicine- The New Indian ... - The New Indian Express

Karolyn Boyd: Master a Healthy Lifestyle – The Story Exchange

Name:Karolyn Boyd

Business: Karolyn Boyd

Location:Gatineau, Canada

Industry:Healthcare, Wellness & FitnessReason for starting?In 1998, I was diagnosed with systemic lupus erythematosus. I was bedridden for two years and was given all these medications and told by the medical community I would be disabled all my life and would not live past 40. I could not accept that and knew there was a better way. I was a kinesiologist and was doing my masters in molecular medicine and specialized in metabolism at the time. It took me about 12 years to heal and I am still on the journey. I have dealt with my medical condition by improving my lifestyle and it is the very tools that saved me that I share with passion with my clients to help them reverse their diabetes. Yoga, meditation, holistic nutrition and exercise. I am now no longer afraid and am the upcoming author of Food Freedom; How to Begin Your Path of Self-Mastery and Reverse Diabetes The New Rules of Living in Todays World. My passion is helping people find their courage to change.

Related:Read about another Healthcare, Wellness & Fitness entrepreneur here. How do you define success?In my job, it is important to help people have a paradigm shift regarding their current way of doing things and helping them realize that there are other options available and that they have the power to do something about it. The choice is always there . . . they simply have to decide to act. Once they have decided, it is important to establish good habits. So success for me is ensuring that the tools that I share with my tribe ultimately bring them independence. They do this by helping them become confident in applying the tools. It takes courage to change and try new options and allow yourself to be open enough to consider another way. This to me, is success when I help someone see other possibilities than their current reality. Biggest success:Reversing diabetes in my clients is my biggest success. When you get the testimonial, you helped save my life, this makes me want to cry out of joy!I want my message to be shared with everyone! I feel it is too important not to. People have to become aware of what they are eating, because how we are currently living at the moment, is killing us. Diabetes is becoming an epidemic and would be completely avoidable if we ate properly. We need to take back our power and find wellness. Brand awareness is super important for me. I feel it is important to start a revolution because our lifestyle is too important. It is for the survival of the human species. I have an online program called Diabetes UTurn which is a 90 day online course to reverse diabetes. I want to sell this course. What is your top challengeand how you have addressed it?I am so passionate about my work that sometimes I forget that it is a business and I have to live from this! I have gotten mentors to assist me. Marcus and Andy are part of the Wellness Leadership Academy and have helped me package my magic and learn how to sell my passion. Scott Oldford has taught me how to do online marketing. I also have local mentors who help me work with my weaknesses and use my strengths to run my business. I also have mentors through my publisher (Black Card Books and Gerry Robert) who are amazing at helping me use my book as a business tool!

In January 2017, I was diagnosed with end stage kidney disease. My lupus has attacked my kidneys. I was on the transplant list as well as needed dialysis. I have since brought my lifestyle up a notch and only eat a certain way, ensure I get 10h of sleep a day and must keep my stress levels to the minimum to survive, but reversed my condition! I still have limited renal function but have absolutely NO pain (which is unheard of for the medical community) and have ample energy, mentally and physically to run my business. I no longer have fear that most people have. I know what real fear is, and it is not being afraid of being your best self. That is nothing compared to the real fear of dying. This is why I am ready to step it up (since January) and decided to go ahead and write this book, which has to come out of me!

Related:How a Mothers Grief Inspired a Mission Who is your most important role model?Jeffrey Bland, the creator of Metagenics. He knows his biochemistry so well and is so inspiring because he uses his intelligence to help people.

Edited by The Story Exchange

Posted: August 7, 2017

View original post here:

Karolyn Boyd: Master a Healthy Lifestyle - The Story Exchange

The business of bottled air – Deutsche Welle

According to the Max Planck Institute for Chemistry, every year more than a million people die in China as a result of air pollution There are other consequences, too: failed harvests, cancelled flights, driving bans. In desperation over the smog in Beijing and Shanghai, inhabitants of the cities have even started importing oxygen in bottles, for 20 dollars apiece. One liter of oxygen is enough for up to 150 inhalations, according toCanadian manufacturers.

Read more: Turning city smog into stunning jewlery

Moses Lam, co-founder of the company Vitality Air, based in Edmonton, Canada, is astonished at his success. In an interview with the television broadcaster CBC he admitted that the whole thing actually started out as a joke. However, when his initial production line of 100 bottles sold out in just four days, he turned it into a professional business.

Clear skies above Canada's Banff National Park

Bestselling mountain air

Vitality Air now has subsidiaries not only in China but also in India, Korea and Vietnam. Every two weeks, 20 employees collect several hundred thousand liters of air in Canada's Rocky Mountains. "Air from the Banff National Park, the first of its kind in Canada, is a bestseller," Moses Lam explains. Production is highly complex, though, as only 20 percent of air is pure oxygen, so it has to be compressed and purified. The precious commodity has a limited shelf-life, too. "The bottles should be used within one or two years," the air salesman recommends.

The Sydney-based company Green & Clean has been filling bottles with Australian air since November 2015 from the Blue Mountains, for example, or the Gold Coast, along the Great Barrier Reef. With a minimum order of 4,000 bottles the Australians have secured a turnover of hundreds of thousands of dollars. Their principal customers come from all over Asia. The company is eyeing Germany as a potential market for the future, a spokesman says, because efforts by car manufacturers, cities and local councils clearly aren't having an effect. He points to the diesel summit as evidence.

The Linde Group sells bottled oxygen

Air as a souvenir

Containers of air may also grace the shelves of some buyers, or their friends as holiday souvenirs. Until now, in the Black Forest, cuckoo clocks have been the souvenir of choice. Elke Ott is offering an alternative to the tradition: She sells Black Forest air. Not bottled, but canned. Entrepreneur Stefan Butz from Bad Kreuznach, on the other hand, prefers clear glass bottles, which he fills with air from the Saarland saltworks.

The Smog Free Tower looks quite futuristic but its purpose is quite grounded: Provide clean air.

Inside the tower is a highly-efficient air filter that consumes very little energy but catches even ultrafine particles. As a result, the air around the tower is up to 75% cleaner than in the city that surrounds it.

Obviously, one tower alone cannot clean the air in the entire city. The idea is more to inspire and provide a space where people can gather, think and breathe freely, even in some of the most polluted cities in the world - in this case, Beijing.

Since Roosegaarde believes in a future where waste does not exist, he had to find some use for the fine particles of pollution that the Smog Free Tower filters out of the air.

Roosegaarde's team decided to take the fine particles and compress them for 30 minutes, before encasing them in acrylic. The result is a stunning cube that gets turned into jewelry like this "Smog Free Ring."

The man behind the project, Dutch designer Daan Roosegaarde wants nothing less than a human right to clean air.

Author: Harald Franzen

Something similar was tried during the soccer world cup in 2006. Back then you could buy "Original Air of Berlin". The joke even preoccupied the Brussels bureaucracy, with the EU warning that more than 30 percent of the tins it analyzed contained high levels of particulate. It didn't stop them going on sale, though.

Along with air as a joke item, there's also bottled air as a political action aimed at improving environmental protection. This was the motivation of Chinese millionaire and philanthropist Chen Guangbiao when he sold bottled air from Chinese rural areas on the streets in 2012.

When the air grows thin

Researchers are already investigating alternatives in case levels of oxygen in the air should drop below the amount we need to breathe.

Naked mole rats can survive a long time in their underground burrows with very little oxygen

They're looking at the idea of limiting oxygen consumption, based on findings by Berlin's Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC). Scientists have discovered that naked mole-rats in their underground burrows can survive for a very long time in suffocating air. In tests, they survived for five hours by absorbing fructose from roots. They would also lower their pulses from 200 to just 50 beats per minute. The scientists are trying to discover whether this could potentially serve as a model for humans. And they've assured us that they have no links to the automobile industry.

Read the original post:

The business of bottled air - Deutsche Welle

Gaining a Deeper Understanding of the Relationship Between DNA and Cell Function – TrendinTech

Have you ever wondered how different cells in the human body do different jobs when every cell contains the entire 6.5 foot, 20,000 gene strand of DNA? A recent study from researchers at the Weatherall Institute of Molecular Medicine, the details of which are published in the journal Nature Cell Biology, have uncovered a key to understanding this question which has puzzled scientists for some time.

A strand of DNA is not full of genes alone and little is understood about the function of the parts in-between. Some parts are known to be enhancers, which activate or deactivate the relevant genes required by the cells but we still dont know how the enhancers know which ones these are.

Inside our cells, DNA is compactly folded in a specific and organized way, allowing the enhancers access to the part of DNA needed for cell function. This organization is clustered in sections called domains, where each domain is responsible for a specific function. Previous research has singled out the protein responsible for this organization as CTCF. The new study focuses on CTCF and its role in the domain which governs a-globin genes, those that regulate the production of hemoglobin.

When functioning correctly, CTCF defined and organized the domains of the DNA in a red blood cell correctly so that the enhancers had appropriate access to the a-globin parts as needed. However, when parts of DNA were removed so that CTCF function was limited, researchers found that the domain boundaries became less pronounced and the gene enhancers activated more than the a-globin genes needed for proper red blood cell function.

This research not only deepens our understanding of the function of DNA in our cell function but also illuminates possible reasons for the malfunction of genes in a number of diseases. This new understanding of the role of CTCF offers a new area of exploration for possible treatments.

More News to Read

comments

See the original post here:

Gaining a Deeper Understanding of the Relationship Between DNA and Cell Function - TrendinTech

Connecticut doctor works to repair central nervous system injuries – Torrington Register Citizen

NEW HAVEN >> There is now no way to regenerate severed nerves in the central nervous system, but Dr. Stephen M. Strittmatter is confident hes found a way to repair them.

Hes even founded a company, ReNetX Bio Inc., to shepherd his new therapy through the maze of regulations, clinical trials and manufacturing processes, ultimately hoping to cure patients with devastating injuries.

We have this amazing, complex neural network that manages all our functions, stemming from the brain and spinal cord, said Strittmatter, professor of neurology and neuroscience in the Yale School of Medicine.

When a nerve fiber, or axon, in the central nervous system is damaged, such as in a paralyzing spinal cord injury, it doesnt grow back. Even though the nerve cell is still healthy in the adult brain or spinal cord, it cant grow and therefore function doesnt come back, he said.

Advertisement

(The central nervous system, which manages all our functions, is separate from the peripheral nervous system, which performs other tasks, such as carrying stimuli from our senses, and which can regenerate.)

The axon, which starts at the cell body, or soma, can extend up to a meter in length, Strittmatter said. If the cell were the size of a baseball, the extension, the nerve fiber, would be the width of a pencil and be a quarter of a mile long, he said.

Strittmatter said he has investigated why nerve fibers cant grow in adults, and that led us to the idea that there are inhibitors that are present in the adult brain and spinal cord. They stop the axons from growing back to where theyre supposed to be.

In fact, there are three such inhibitors, called Nogo, MAG and OMgp, which exist in the myelin that coats the nerve fibers. They stick to the axon and tell it not to grow, Strittmatter said.

He and the researchers in his lab studied ways to stop the inhibitors from attaching to the axon. So we developed this protein, which we call Nogo Trap Its sort of like a double negative; it blocks the inhibitors [and] those new connections allow function to be recovered, he said.

So far, the therapy looks promising. Weve done experiments here that have shown that that works after rats and mice have spinal cord injuries, he said.

Now, ReNetX Bio, a new name for a company founded in 2010 as Axerion Therapeutics, faces the long process of turning an experimental therapy into a marketable drug, which they hope also will be effective for stroke and glaucoma.

Thats what the company is about, bringing it out of the lab and into the clinic, Strittmatter said.

The next step is getting Food and Drug Administration approval of Nogo Trap, also known as Axer-204, as an investigative new drug, which allows phase one clinical trials. That initial phase is only concerned with the drugs safety. The second and third phases test whether or not the drug is effective.

Erika R. Smith, named CEO of ReNetX in July, said there is a long list of other tasks to be addressed, including toxicology testing, scaling up manufacture of the drug and lots of paperwork. A lot of boxes get checked to make sure its OK to try in a clinical setting, she said.

Both Smith and Strittmatter said there are advantages to forming their own company.

I guess I feel like being involved I can help make sure that the right clinical trials are done, Strittmatter said.

Smith added, Theres a lot of challenges in early research that a lot of pharma companies arent willing to take the risk themselves. A lot of times companies wont come in really early.

Along the way, theres all kinds of roadblocks, things we cant expect, Strittmatter said. Drugs might get degraded faster in one species than another or there could be secondary complications like infections.

Were very excited that the experiments that have happened in the lab have gone very well, he said. However, there is a risk. Experimental animal studies can look great but maybe only 20 percent of the time can that be turned into a drug that can be used in people, he said.

But Smith noted the substantial funding that has come into the company to this point were estimating $15 million that has gotten the program to where it is. Much of that support has come from the National Institutes of Health, she said.

The company has a staff of five and is seeking to hire a chief medical officer, Smith said.

Yale University holds intellectual property rights and is a part owner of ReNetX. The company has licensed those patents from Yale so they can go on to do sales and clinical development, Strittmatter said. Yale would receive royalties if it were eventually sold as a drug.

The end goal that it gets to people and it makes a difference in their lives, Strittmatter said.

Smith said, The big picture of this is its a whole new paradigm change for any kind of injury in the central nervous system.

Call Ed Stannard at 203-680-9382.

Read this article:

Connecticut doctor works to repair central nervous system injuries - Torrington Register Citizen

New Research Shows the Power of Radiomics to Improve Precision Medicine – Lab Manager Magazine

TAMPA, Fla. Precision medicine has become the leading innovation of cancer treatment. Patients are routinely treated with drugs that are designed to target specific tumors and molecules. Despite the progress that has been made in targeted cancer therapies, the path has been slow and scientists have a long road ahead. In a collaborative project, researchers at theMoffitt Cancer CenterandDana-Farber Cancer Instituteinvestigated the emerging field of radiomics which has the potential to improve precision medicine by non-invasively assessing the molecular and clinical characteristics of lung tumors.Their workwas published in the July 21 issue ofeLIFE, a novel, emerging journal in biomedicine founded by National Academy members and Nobel Prize winners.

Radiomics offers scientists and clinicians a novel way to analyze individual tumors for their biology, guide cancer treatment, and predict response to therapy. Virtually every cancer patient has their tumor imaged though computed tomography (CT), magnetic resonance (MRI), and/or positron emission tomography (PET) as standard-of-care. The images allow physicians to determine the stage and location of a tumor and guide treatment decisions. But with recent advances in computer generated data and models, these images are now being used in the field of radiomics to extract high-dimensional data that can be used to guide precision medicine. By using radiomics, scientists are able to objectively quantitate different features of tumors, such as intensity, shape, size, and texture. These data can then be used in combination with genetic and clinical data to predict active biological pathways, clinical outcomes, and potential effective therapies.

The core belief of radiomics is that images arent pictures, theyre data. We have to treat them as data. Right now, we extract about 1300 different quantitative features from any volume of interest, saidRobert Gillies, PhD, chair of MoffittsDepartment of Cancer Imaging and Metabolism.

This collaboration analyzed CT image features from 262 North American patients and 89 European patients with non-small cell lung cancer (NSCLC). They identified associations between the image features and molecular markers, biological pathways, and clinical outcomes. For example, they determined that certain sets of image features could predict the overall survival of NSCLC patients, while other image features could predict the stage of the tumor or the presence of biological and genetic markers that drive tumor growth. The researchers also demonstrated the clinical importance of radiomics by showing that it is possible to increase prognostic power by combining radiomic data with genetic information and clinical data.

We already knew that radiomic algorithms have strong clinical importance; however, the biological basis for these observations remained unknown. This study now answers this key question for the first time by defining and independently validating the driving biological pathways of radiomic phenotypes saidHugo Aerts, PhD, director of theComputational Imaging and Bioinformatics Laboratoryand associate professor of Radiation Oncology atHarvard Medical School.

Radiomics has several advantages over other commonly used techniques that guide precision medicine. Currently, biological markers are routinely analyzed with tissue biopsies that are invasive, collected only at the beginning of care, and may not accurately reflect the biology of the entire tumor. In contrast, imaging techniques are noninvasive and can provide information about the entire tumor throughout the entire course of treatment and response. Additionally, the majority of cancer patients routinely have images taken for diagnostic purposes already, making radiomics a cost-effective approach.

This study advances the molecular knowledge of radiomic characterization of tumors, information currently not used clinically. This may provide opportunities to improve decision-support in all patients as imaging is routinely used in clinical practice as standard of care, said Gillies.

The study was supported partly by funds from the Tissue Core Facility at Moffitt Cancer Center.

Read more here:

New Research Shows the Power of Radiomics to Improve Precision Medicine - Lab Manager Magazine

Grappling with graduate student mental health and suicide – The Biological SCENE

[+]Enlarge

Credit: Will Ludwig/C&EN/Shutterstock

In brief

Last year, Scripps Research Institute California graduate student Anna Owensby killed herself. Graduate school is hard at the best of times, and it can become overwhelming when students are faced with situations such as having a dispute with an adviser or not passing a milestone such as a qualifying exam. One recent study found that 7.3% of graduate students had suicidal thoughts. But there are practices that advisers, departments, and schools can put in place to support their students mental health.

In the spring of 2016, Scripps Research Institute California graduate student Anna Owensby texted a friend: I have this feeling right now that there isnt really a place for me ... People like me arent supposed to get a Ph.D., we are addicts or homeless or in jail.

Owensby, 26, was a fourth-year graduate student. In her first years at Scripps, she was briefly hospitalized to evaluate her mental health, and she changed lab groups. Her new adviser, Scripps molecular medicine professor Dennis W. Wolan, had assisted in finding her a therapy group that seemed to be helping her. The group was not in Owensbys insurance network, but Scripps was paying for the sessions. She passed her Ph.D. candidacy exam at the end of 2015, at which time her committee members indicated that she was progressing appropriately and that they had no nonacademic concerns about her.

Then, in the space of just a few weeks in spring 2016, Owensby was banned from Wolans lab and told not to contact him or her lab mates. She was encouraged to resign from Scripps and informed that Wolan would not give her a job recommendation.

On April 14, 2016, Owensby died by suicide.

There is no one situation or event that makes a person suicidal, experts in suicide risk and prevention emphasize. We always want to come up with one cause, but it doesnt work that way, says Jill Harkavy-Friedman, vice president of research at the American Foundation for Suicide Prevention. People end their lives when a number of conditions and factors come together to make someone feel overwhelmed and unable to cope.

Nonetheless, there are concrete steps that academic advisers, departments, and schools can take to better support their graduate students mental health and reduce the risk of losing people like Owensby.

In 2015, the rate of death by suicide for people ages 20 to 34 in the U.S. was between 15 and 16 people per 100,000, according to the Centers for Disease Control & Prevention. Suicide is one of the five most common causes of death for people ages 15 to 44 years.

Long-term factors that increase the risk that someone might attempt suicide include a psychiatric diagnosis, substance use disorder, childhood trauma, and family history of suicide.

Few studies have investigated mental health problems and suicide in Ph.D. students specifically. One survey of 3,659 students in Belgium suggests that 32% of Ph.D. students are at risk of having or developing a psychiatric disorder such as depression (Res. Policy 2017, DOI: 10.1016/j.respol.2017.02.008). A separate survey of 301 graduate students at Emory University determined that more than 34% likely had moderate to severe depression, while 7.3% reported suicidal thoughts, and 2.3% reported having plans for suicide (Acad. Psychiatry 2014, DOI: 10.1007/s40596-014-0041-y). The rates of mental health issues in this population are elevated pretty significantly above the general population, says Nathan L. Vanderford, assistant dean for academic development in the University of Kentucky College of Medicine.

In addition to the long-term factors that increase suicide risk, short-term issues such as life transitions and stress also play a role, experts say. Not unlike starting college, the transition to graduate school can involve significant life upheavalbut without the large number of support staff and peers that undergraduates encounter when moving to campus.

Graduate students instead might move to a new location to live in an apartment alone or with a rarely seen roommate and then interact mostly with a relatively small set of classmates and lab mates in one or two buildings. As time goes on, other events can disrupt a students world: An adviser loses a grant, doesnt get tenure, or chooses to move, or a student fails to pass a milestone such as an oral exam. Meanwhile, family and friends might not understand the unique experience of graduate school.

And the stakes are high. Students are putting so much effort and energy into pursuing the degree that every single step can carry a lot of weight. Certainly theres fear of failure or perception of failure, says Christa Labouliere, a clinical psychology professor and administrator for a suicide prevention program at New York State Psychiatric Institute, which is part of Columbia University Medical Center.

A year after Anna Owensby died, her mother, Victoria Owensby, sobs when she tries to talk about her. She was so funny, her heart was so kind, and she was beautiful and brilliant, Victoria says.

Anna Owensby was valedictorian of her high school class and a talented cellist who enjoyed playing music composed by Johann Sebastian Bach. After high school, she initially attended Cleveland Institute of Music. Students at the institute take nonmusic electives at nearby Case Western Reserve University. After a general chemistry class, Owensby reconsidered her career pathshe didnt think she could make money playing the cello, her mother saysand Owensby wound up switching to a chemistry major at Case.

32%

Percentage of Ph.D. students who are at risk of having or developing a psychiatric disorder such as depression, according to a 2017 study. Source: Res. Policy 2017, DOI: 10.1016/j.respol.2017.02.008

2.3%

Percentage of surveyed graduate students who reported having plans to attempt suicide, according to a 2014 study. Source: Acad. Psychiatry 2014, DOI: 10.1007/s40596-014-0041-y

15 to 16

People ages 2034 per 100,000 who died by suicide in the U.S. in 2015. Source: Centers for Disease Control & Prevention

25

People who attempt suicide for every person who dies by suicide. Source: American Foundation for Suicide Prevention

As an undergraduate, Owensby stood out for her enthusiasm and work ethic, says Case chemistry professor Gregory Tochtrop, who taught Owensby organic chemistry before recruiting her to do research in his lab. She was incredibly smart, Tochtrop says. After discussing a research idea, she would track down and read all the same papers a more seasoned scientist would look up. She had the mind-set of Im going to learn something about this so that I can contribute to it, he says.

But Owensby had difficulties as well. Growing up in Greenville, S.C., she was a tough child to parent, often losing emotional control when faced with even minor setbacks, her family says. One of Owensbys aunts, Amy Forton, is a mental health counselor and says Owensby exhibited severe anxiety. She wasnt depressed, though, Forton believes. She was happy and interested in things in life.

Nevertheless, Owensbys difficulty regulating her emotions was significant enough that her mother sought psychological help for her daughter. The therapists just said she was really, really smart and overly perfectionist and sensitive, her mother says. They never said anything about any mental illness, ever.

There were mental health issues in Owensbys family. Her father had alcoholism and died of liver disease while she was in college. Tochtrop believes that the challenges of growing up with her fathers alcoholism and then losing him led Owensby to look for father figures. Owensby tried to push for a more personal connection in an otherwise professional relationship with him, Tochtrop says. Early in college, Owensby would turn to Tochtrop to talk for hours about her life history and problems. It wasnt anything inappropriate, but I think she was looking for things she didnt have, Tochtrop says.

When Owensby was a junior, Tochtropat the time an assistant professor who had a wife in law school, a baby, and an approaching tenure decisionfelt he had to draw a line. He told Owensby that he couldnt help her with personal matters, but he was happy to support her career. Owensby seemed to take the message well, and after the conversation we still had a really good professional relationship, he says.

Owensby used Case counseling services, Tochtrop says, but he doesnt know further details. Once, he noticed that she had been cutting herself. Despite her personal challenges, Owensby graduated from Case having earned several university awards, including one for best thesis in undergraduate chemistry research.

Owensby started at Scripps in 2012. Details of her time there are based on materials provided by and interviews with her family and Tochtrop, who stayed in close touch after she left Case. Scripps refused C&ENs request to interview institute personnel about Owensby and the schools programs to support students mental health. In a statement, Vice President for Communications and Development Cara Miller said, All universities are faced with the challenge of wanting to provide the utmost support for members of their community who may be in need of assistance, while also maintaining their privacy and adhering to legal requirements. Owensbys mother has filed a complaint with Scrippss accrediting commission because although the institute has given her Owensbys educational records, it has withheld disciplinary records.

Anna Owensby (center) with her mother, Victoria Owensby, and her brother, Adam Owensby.

Credit: Courtesy of Anna Owensbys family

During her first years at graduate school, Owensby diagnosed herself with borderline personality disorder (BPD). In January 2015, she began a form of cognitive behavioral therapy with the support of her adviser, Wolan, and Scripps. The director of the therapy center that Owensby used, Milton Z. Brown of the Dialectical Behavior Therapy Center of San Diego, did not respond to voice mail messages left by C&EN.

The National Institute of Mental Health describes BPD as a serious mental disorder marked by a pattern of ongoing instability in moods, behavior, self-image, and functioning. People with BPD often exhibit impulsive actions and have unstable relationships. They go through episodes of anger, depression, and anxiety that can last only a few hours or as long as days. Because Brown did not return C&ENs calls, C&EN was unable to determine whether Owensbys therapists agreed with her self-diagnosis.

An unfortunate consequence of Wolans support in the face of Owensbys mental health challenges may have been that Owensby again sought personal fulfillment in a professional relationship. Looking back, I am just so incredibly grateful for the times you gave me when I felt valued and wanted, as they were the happiest moments of my life, she wrote to Wolan in a letter she last edited a few days before she died. I slowly came to love you like the family I had always wanted.

On Sunday, March 13, 2016, Owensby seemed to be doing well at Scripps. Wolan had texted Owensby, You are working harder than you likely ever have in your life. Andmore importantlyholding it together. Youve come an incredibly long way. Very proud of you! according to a document Owensby later prepared for attorneys.

Then Owensbys life quickly derailed. According to Owensbys notes, on Wednesday, March 16, Wolan called her into his office to ask if shed gone through the drawers of a lab mate with whom Owensby had had a contentious relationship. (Six months earlier, Owensby had suspected the lab mate of sabotaging her research materials.)

On Thursday, March 17, Owensby was unexpectedly escorted from her lab to meet with James R. Williamson, then dean of graduate studies at Scripps and now executive vice president for research and academic affairs. According to Owensbys notes about the meeting, Williamson told her that Wolan had requested her removal because she was disruptive and had gone through other lab members personal property. Williamson told Owensby not to return to the lab and had her identification badge and keys confiscated. Then she was escorted to her car.

On Friday, March 18, Scripps director of graduate studies, Dawn Eastmond, contacted Owensby to ask about laboratory materials needed to continue experiments. Eastmond also told her not to contact Wolan or any of her lab mates.

Owensby considered hiring an attorney to challenge Scrippss actions but decided she couldnt afford one. At a meeting on Thursday, March 31, 2016, with Williamson and Eastmond, Owensby learned more details of why shed been shut out of Scripps. In addition to the accusation about going through lab mates property, Wolan had discovered that in 2014 Owensby and another lab member had accessed Wolans computer and gone through his web browser history.

In her notes for possible attorneys, Owensby maintained that the other, more senior, lab member was the instigator and she was a bystander. She felt an enormous amount of social pressure to laugh along with the other lab member when they were searching Wolans computer because of a fear of harassment from that person, Owensby wrote. Owensby also alleged that the other lab member had a history of inappropriate behavior, including using lab resources without Wolans knowledge to generate materials for a project the lab member planned to undertake elsewhere.

In texts to a friend after the meeting, Owensby wrote about the next steps Scripps planned to take: They say they have conflicting testimony. They will basically feel it out and [Eastmond], [Williamson], and a [Scripps] lawyer will make a decision. [Eastmond] told me she envisions that either I resign or get terminated.

Over the next couple of weeks, Owensby continued to text the same friend, expressing concern about how long Scripps would continue to pay her and whether she would have enough money for rent. She also said that she was applying for jobs, but even McDonalds wants to talk to your previous supervisor, she wrote. I dont know what Im gonna do.

Owensby also met with Brown, one of her therapists. He later told her family that he tried to help her problem solve throughout the entire course of events. Around Tuesday, April 5, Owensby called Eastmond from Browns office to ask about getting a recommendation from Wolan. Owensby texted a friend that Eastmond said Wolan didnt want anything to do with her.

On Wednesday, April 13, 2016, Eastmond called Owensby to suggest that she resign from Scripps. Owensbys texts to a friend say that Scripps would pay her until the end of April. After Owensby died, Forton, her aunt, spoke with Wolan and Eastmond. According to Fortons notes about the meeting, Eastmond says she informed Owensby that Scripps would continue to pay for her health insurance through June.

On Wednesday and Thursday, April 13 and 14, Owensby tried several times to contact Wolan. She also spoke for the last time with Tochtrop, who says he thinks about the conversation nearly every day. She was worried about her career and what she could do, Tochtrop recalls. I really tried to emphasize how incredibly smart and talented she was. I said that I would do anything I could to make sure she had a safe landing and found a position.

Meanwhile, Owensby also spoke with and texted friends. Can you watch Curie for a little bit tonight, she texted one on Wednesday, referring to her beloved dog. I need to have some time alone.

The friend wasnt able to take Curie that evening, and Owensby repeated the request on Thursday. Wolan and Eastmond each contacted Owensbys therapist that day, concerned about Owensbys behavior. No one contacted Owensbys family.

Thursday evening, Owensby killed herself.

We deeply mourn Annas sudden passing, Williamson said in a Scripps obituary. She was extremely bright and truly passionate about science. Our sympathies go out to her family, close friends and colleagues. We are all struggling to come to terms with what has happened, and we are doing our best to come together to generate a support network for those most affected.

Cultivating mental health

Given Owensbys mental health history, she was at high risk for attempting suicide after Scripps personnel barred her from her lab and encouraged her to resign. Ideally, Scripps personnel and Owensbys therapists would have been aware of her risk for suicide.

Generally, however, predicting suicide is hard, says Sidra J. Goldman-Mellor, who studies suicide risk as a professor of public health at the University of California, Merced. For any given person in a program, its going to be really difficult to know if theyre at high risk for suicide, because a lot of people hide it. What that means is that its important to make sure there is support for all students.

That support should go beyond sending an annual e-mail with a list of resources, suicide risk and prevention experts say. Additional steps to take might include holding events such as stress-management workshops or sponsoring thesis-writing support groups. You want to make it a culture in the department to acknowledge that graduate school is hard and there are things you can do to help cope with it, Columbias Labouliere says. Maybe then people wont get to the point of feeling trapped.

Some chemistry departments are making efforts to reduce stress where they can, foster more open discussions about mental health, and encourage students to talk with each other.

When Philippe Buhlmann, a chemistry professor at the University of Minnesota, became his departments director of graduate studies, he made it his mission in that role to promote mental health. He started by working with UMNs mental health services to develop a survey of chemistry graduate students to figure out their primary stressors. The most intense ones turned out to be the interrelated needs to publish and to find a job upon graduation. We cant eliminate those, Buhlmann says. We want 100% of our students to get a job.

But Buhlmann and colleagues did identify some measures that the department could take to reduce students stress. For example, the department reconsidered annual student progress reports and self-evaluations. Without guidance, some students are harder on themselves than they should be. They come up with their own scale that by all objective assessment is twisted, Buhlmann says. Now, after the students self-evaluate, their advisers must also weigh in to concur or correct the students assessment, clarifying expectations and improving communication in the process.

The department also now requires that fourth-year students meet with their thesis committee members to talk about research progress and career aspirations. Students were worried that this would be just another hoop to jump through, Buhlmann says. But Im getting very positive feedback. It gives students other perspectives and pushes them to think more realistically about how to reach their postgraduation goals.

Buhlmann also formed a student-run group called the Community of Chemistry Graduate Students (CCGS) that has a $3,000 budget to plan events promoting physical, mental, and social health. Activities so far have included hosting weekly runs and biweekly social hours, creating videos about depression, and holding panel discussions on topics such as stress reduction or how to write a rsum. If we have too many things that are too strongly focused on mental health, then we dont get good turnout, says third-year chemistry graduate student and CCGS chair Evan Anderson. If we mix things up, then we get better attendance overall. A recent picnic had 150 attendees, which included more than half of the graduate students in the department.

Similar efforts are afoot in the department of chemistry and chemical biology at Harvard University. That department tried to implement changes after graduate student Jason Altom died by suicide in 1988at the time, the departments fourth suicide death in eight years. Some of those efforts, such as a biweekly catered dinner, didnt stick.

A switch to multiprofessor doctoral committees did lastbut different faculty approached committee responsibilities differently, such as how often they met with students. Starting with this falls incoming class, however, there will be some standardization: To alleviate the stress of having to choose committee members and corral them for meetings, those tasks will fall to the departments director of graduate studies. Starting in their second year, students will have annual meetings with their committee in April, and the department has developed some basic guidelines about what those meetings should cover.

Additionally, the department has formed a Community Committee composed of faculty, staff, students, and postdocs who are charged with promoting department cohesiveness and communication. It has sponsored a Thanksgiving dinner for people remaining in the Cambridge, Mass., area during the holiday; sessions on mindfulness; chair massages; and Fruitful Wednesdays during nutritional awareness month, when students can gather and chat while picking up free fruit to eat. The committee does not yet have a budget because it is new, but money is not a constraint; we will do things as they make sense, says Elizabeth A. Lennox, director of laboratories and codirector of graduate studies in the department.

Meanwhile, the departments Graduate Student & Postdoc Council has a $19,000 annual budget for social gatherings and what Lennox calls fun but academically constructive events. For example, the committee organized faculty to give talks about their experiences applying for academic jobs, running a lab, and rising from junior to senior faculty.

The increased efforts toward supporting mental health and building community were a priority set by professor Charles M. Lieber when he became department chair in 2015. A culture survey had shown that morale was down across the board in the department, something that Lieber attributes to a lack of transparency. Lieber emphasizes that expectations remain high for Harvard students, postdocs, and faculty. But promoting openness helps alleviate some of the issues created when people stay in their labs and offices and dont talk with each other, he adds.

Although general programs to promote mental, physical, and social health are important, it is also critical for people to know how to respond when someone is in acute distress. Owensby was already connected with therapists when her life upended. But most people who are depressed or suicidal dont make it to a counseling center, says Julie Cerel, a psychologist and professor at the University of Kentucky College of Social Work and president of the American Association of Suicidology. She says training people who are naturally part of students environmentgatekeepers such as lab managers, faculty, and other departmental staffcan help identify those in need of intervention. In departments in which people arent used to discussing mental health, training can also provide scripts they can use to begin conversations.

Anna Owensby with her dog, Curie.

Credit: Courtesy of Anna Owensbys family

Such training, however, doesnt mean that faculty or other department members become therapists. There are professional limitations and personal boundaries that should not be crossed, UMNs Buhlmann emphasizes. He was a pilot trainee in a now-expanding effort at UMN to train mental health advocates within each academic unit. The advocates are taught a 4R approach: recognize when people are in trouble, assume the role of listener, respond by giving them options, and direct them to appropriate resources.

Additionally, Buhlmann brought in UMN mental health services staff to train graduate student teaching assistants to recognize the signs of stress and mental health problems in chemistry undergraduates and how to direct them to appropriate help. These skills could also transfer to interactions with peers.

At Harvard, Lennox arranged for the schools mental health services to conduct mental health awareness training this spring for the lab group administrators within her department. These administrators might be physically present in labs and see members in person more often than faculty do, Lennox says.

Lennox is also working with mental health services to develop a mental health curriculum to add to the departments routine training for students and postdocs. Shed like to include topics such as signs of mental distress, suicide risk awareness, and campus resources.

As part of an overall campus approach, schools should also ensure that on-campus clinicians are trained in suicide prevention response and how to implement measures that can quickly ensure someones safety, Labouliere says. Those interventions include determining how to restrict access to whatever method someone has chosen to use to attempt suicide. One of the reasons someone is suicidal is an impaired ability to solve problems. Consequently, once someone has a suicide plan, he or she is unlikely to change it when faced with a barrier. Another intervention is safety planning, which involves talking through and writing down what actions to take when suicidal thoughts take over.

Suicidal thinking does not last forever, Labouliere notes. In the moment, people might find their pain unbearable, but if they can get through that crisis, then they likely can engage in therapy, consider their options, and work to address whatever factors led to the situation. She adds that its important to tell people in crisis that effective, research-supported treatments are available. A lot of folks that feel suicidal are so hopeless and feel that their problems are so intractable that the message that there are treatments can be very powerful, she says.

If someone does die by suicide, its important for the department and school to step up actions to pay attention to their community. Cerels research suggests that after someone dies by suicide, as many as 30 people might have their lives majorly disrupted. Its not just a handful of close family members whose lives are changed, she says. Also, I think that suicides can really hit science departments hard because theyre not used to talking about feelings, she says.

Since Buhlmann has started bringing up the topic of mental health in his department, theres been tremendously positive feedback from other faculty, he says. Anyone whos been a chemistry professor long enough knows students in their group or department who have severely struggled, he adds. There are so many good people out there who want to help but dont know how. When you start to talk about it, everyone engages.

More:

Grappling with graduate student mental health and suicide - The Biological SCENE

New Haven doctor works to repair central nervous system injuries – New Haven Register

Photo: Arnold Gold / Hearst Connecticut Media

Erika R. Smith, CEO of ReNetX Bio Inc., is photographed with Dr. Stephen M. Strittmatter, founder of the company, in his lab at the Boyer Center for Molecular Medicine in New Haven.

Erika R. Smith, CEO of ReNetX Bio Inc., is photographed with Dr. Stephen M. Strittmatter, founder of the company, in his lab at the Boyer Center for Molecular Medicine in New Haven.

New Haven doctor works to repair central nervous system injuries

NEW HAVEN >> There is now no way to regenerate severed nerves in the central nervous system, but Dr. Stephen M. Strittmatter is confident hes found a way to repair them.

Hes even founded a company, ReNetX Bio Inc., to shepherd his new therapy through the maze of regulations, clinical trials and manufacturing processes, ultimately hoping to cure patients with devastating injuries.

We have this amazing, complex neural network that manages all our functions, stemming from the brain and spinal cord, said Strittmatter, professor of neurology and neuroscience in the Yale School of Medicine.

When a nerve fiber, or axon, in the central nervous system is damaged, such as in a paralyzing spinal cord injury, it doesnt grow back. Even though the nerve cell is still healthy in the adult brain or spinal cord, it cant grow and therefore function doesnt come back, he said.

(The central nervous system, which manages all our functions, is separate from the peripheral nervous system, which performs other tasks, such as carrying stimuli from our senses, and which can regenerate.)

The axon, which starts at the cell body, or soma, can extend up to a meter in length, Strittmatter said. If the cell were the size of a baseball, the extension, the nerve fiber, would be the width of a pencil and be a quarter of a mile long, he said.

Strittmatter said he has investigated why nerve fibers cant grow in adults, and that led us to the idea that there are inhibitors that are present in the adult brain and spinal cord. They stop the axons from growing back to where theyre supposed to be.

In fact, there are three such inhibitors, called Nogo, MAG and OMgp, which exist in the myelin that coats the nerve fibers. They stick to the axon and tell it not to grow, Strittmatter said.

He and the researchers in his lab studied ways to stop the inhibitors from attaching to the axon. So we developed this protein, which we call Nogo Trap Its sort of like a double negative; it blocks the inhibitors [and] those new connections allow function to be recovered, he said.

So far, the therapy looks promising. Weve done experiments here that have shown that that works after rats and mice have spinal cord injuries, he said.

Now, ReNetX Bio, a new name for a company founded in 2010 as Axerion Therapeutics, faces the long process of turning an experimental therapy into a marketable drug, which they hope also will be effective for stroke and glaucoma.

Thats what the company is about, bringing it out of the lab and into the clinic, Strittmatter said.

The next step is getting Food and Drug Administration approval of Nogo Trap, also known as Axer-204, as an investigative new drug, which allows phase one clinical trials. That initial phase is only concerned with the drugs safety. The second and third phases test whether or not the drug is effective.

Erika R. Smith, named CEO of ReNetX in July, said there is a long list of other tasks to be addressed, including toxicology testing, scaling up manufacture of the drug and lots of paperwork. A lot of boxes get checked to make sure its OK to try in a clinical setting, she said.

Both Smith and Strittmatter said there are advantages to forming their own company.

I guess I feel like being involved I can help make sure that the right clinical trials are done, Strittmatter said.

Smith added, Theres a lot of challenges in early research that a lot of pharma companies arent willing to take the risk themselves. A lot of times companies wont come in really early.

Along the way, theres all kinds of roadblocks, things we cant expect, Strittmatter said. Drugs might get degraded faster in one species than another or there could be secondary complications like infections.

Were very excited that the experiments that have happened in the lab have gone very well, he said. However, there is a risk. Experimental animal studies can look great but maybe only 20 percent of the time can that be turned into a drug that can be used in people, he said.

But Smith noted the substantial funding that has come into the company to this point were estimating $15 million that has gotten the program to where it is. Much of that support has come from the National Institutes of Health, she said.

The company has a staff of five and is seeking to hire a chief medical officer, Smith said.

Yale University holds intellectual property rights and is a part owner of ReNetX. The company has licensed those patents from Yale so they can go on to do sales and clinical development, Strittmatter said. Yale would receive royalties if it were eventually sold as a drug.

The end goal that it gets to people and it makes a difference in their lives, Strittmatter said.

Smith said, The big picture of this is its a whole new paradigm change for any kind of injury in the central nervous system.

Call Ed Stannard at 203-680-9382.

Read more from the original source:

New Haven doctor works to repair central nervous system injuries - New Haven Register

New Haven doctor works to repair central nervous system injuries – New Haven Register (blog)

Photo: Arnold Gold / Hearst Connecticut Media

Erika R. Smith, CEO of ReNetX Bio Inc., is photographed with Dr. Stephen M. Strittmatter, founder of the company, in his lab at the Boyer Center for Molecular Medicine in New Haven.

Erika R. Smith, CEO of ReNetX Bio Inc., is photographed with Dr. Stephen M. Strittmatter, founder of the company, in his lab at the Boyer Center for Molecular Medicine in New Haven.

New Haven doctor works to repair central nervous system injuries

NEW HAVEN >> There is now no way to regenerate severed nerves in the central nervous system, but Dr. Stephen M. Strittmatter is confident hes found a way to repair them.

Hes even founded a company, ReNetX Bio Inc., to shepherd his new therapy through the maze of regulations, clinical trials and manufacturing processes, ultimately hoping to cure patients with devastating injuries.

We have this amazing, complex neural network that manages all our functions, stemming from the brain and spinal cord, said Strittmatter, professor of neurology and neuroscience in the Yale School of Medicine.

When a nerve fiber, or axon, in the central nervous system is damaged, such as in a paralyzing spinal cord injury, it doesnt grow back. Even though the nerve cell is still healthy in the adult brain or spinal cord, it cant grow and therefore function doesnt come back, he said.

(The central nervous system, which manages all our functions, is separate from the peripheral nervous system, which performs other tasks, such as carrying stimuli from our senses, and which can regenerate.)

The axon, which starts at the cell body, or soma, can extend up to a meter in length, Strittmatter said. If the cell were the size of a baseball, the extension, the nerve fiber, would be the width of a pencil and be a quarter of a mile long, he said.

Strittmatter said he has investigated why nerve fibers cant grow in adults, and that led us to the idea that there are inhibitors that are present in the adult brain and spinal cord. They stop the axons from growing back to where theyre supposed to be.

In fact, there are three such inhibitors, called Nogo, MAG and OMgp, which exist in the myelin that coats the nerve fibers. They stick to the axon and tell it not to grow, Strittmatter said.

He and the researchers in his lab studied ways to stop the inhibitors from attaching to the axon. So we developed this protein, which we call Nogo Trap Its sort of like a double negative; it blocks the inhibitors [and] those new connections allow function to be recovered, he said.

So far, the therapy looks promising. Weve done experiments here that have shown that that works after rats and mice have spinal cord injuries, he said.

Now, ReNetX Bio, a new name for a company founded in 2010 as Axerion Therapeutics, faces the long process of turning an experimental therapy into a marketable drug, which they hope also will be effective for stroke and glaucoma.

Thats what the company is about, bringing it out of the lab and into the clinic, Strittmatter said.

The next step is getting Food and Drug Administration approval of Nogo Trap, also known as Axer-204, as an investigative new drug, which allows phase one clinical trials. That initial phase is only concerned with the drugs safety. The second and third phases test whether or not the drug is effective.

Erika R. Smith, named CEO of ReNetX in July, said there is a long list of other tasks to be addressed, including toxicology testing, scaling up manufacture of the drug and lots of paperwork. A lot of boxes get checked to make sure its OK to try in a clinical setting, she said.

Both Smith and Strittmatter said there are advantages to forming their own company.

I guess I feel like being involved I can help make sure that the right clinical trials are done, Strittmatter said.

Smith added, Theres a lot of challenges in early research that a lot of pharma companies arent willing to take the risk themselves. A lot of times companies wont come in really early.

Along the way, theres all kinds of roadblocks, things we cant expect, Strittmatter said. Drugs might get degraded faster in one species than another or there could be secondary complications like infections.

Were very excited that the experiments that have happened in the lab have gone very well, he said. However, there is a risk. Experimental animal studies can look great but maybe only 20 percent of the time can that be turned into a drug that can be used in people, he said.

But Smith noted the substantial funding that has come into the company to this point were estimating $15 million that has gotten the program to where it is. Much of that support has come from the National Institutes of Health, she said.

The company has a staff of five and is seeking to hire a chief medical officer, Smith said.

Yale University holds intellectual property rights and is a part owner of ReNetX. The company has licensed those patents from Yale so they can go on to do sales and clinical development, Strittmatter said. Yale would receive royalties if it were eventually sold as a drug.

The end goal that it gets to people and it makes a difference in their lives, Strittmatter said.

Smith said, The big picture of this is its a whole new paradigm change for any kind of injury in the central nervous system.

Call Ed Stannard at 203-680-9382.

More:

New Haven doctor works to repair central nervous system injuries - New Haven Register (blog)